Aclaris Therapeutics Announces Formation of New Scientific Advisory Board
December 15 2020 - 7:00AM
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage
biopharmaceutical company focused on developing novel drug
candidates for immuno-inflammatory diseases, today announced the
formation of a new Scientific Advisory Board consisting of Stanley
Cohen, MD, Marco Colonna, MD, James Krueger, MD, PhD, and Michael
Weinblatt, MD.
“We are looking forward to working with each of these leading
experts in rheumatology and other immuno-inflammatory diseases,”
said Dr. David Gordon, Chief Medical Officer of Aclaris. “Their
collective wealth of knowledge and expertise will be extremely
beneficial to us as we continue to advance our immuno-inflammatory
programs.”
The members of the Scientific Advisory Board are:
Stanley Cohen, MD
Dr. Stanley Cohen is a physician at Rheumatology Associates, a
Clinical Professor in the Department of Internal Medicine and a
Clinical Faculty Member in the Division of Rheumatology at UT
Southwestern Medical School, a Co-Director of the Division of
Rheumatology at Presbyterian Hospital, Dallas, and a Co-Medical
Director of Metroplex Clinical Research Center. He is a past
president of the American College of Rheumatology and in 2016 was
designated as a Master by the American College of Rheumatology. Dr.
Cohen is board certified in internal medicine and rheumatology.
Marco Colonna, MD
Dr. Colonna is the Robert Rock Belliveau, M.D. Endowed Professor
of Pathology, a Professor of Immunobiology, a Professor of Medicine
and the Head of Colonna Lab at the Washington University School of
Medicine in St. Louis. Dr. Colonna is a member of the National
Academy of Sciences.
James Krueger, MD, PhD
Dr. Krueger is the D. Martin Carter Professor in Clinical
Investigation and Head of the Laboratory of Investigative
Dermatology at The Rockefeller University. He also serves as the
Chief Executive Officer, a Co-Director for the Center for Clinical
and Translational Science and Senior Attending Physician at The
Rockefeller University Hospital. Dr. Krueger has received numerous
awards, including the Eugene J. Van Scott Award for Innovative
Therapy of the Skin by the American Academy of Dermatology in 2015,
the Astellas Award by the American Academy of Dermatology in 2010
and the Farber Award by the Society of Investigative Dermatology in
2010. Dr. Krueger is board certified in dermatology.
Michael Weinblatt, MD
Dr. Weinblatt is the Co-Director of Clinical Rheumatology at the
Brigham and Women’s Hospital. He is also the John R. Riedman
Professor of Medicine at Harvard Medical School. Dr. Weinblatt is a
past president of the American College of Rheumatology. He was
awarded the Presidential Gold Medal by the American College of
Rheumatology in 2017 and is a Master of the American College of
Rheumatology. Dr. Weinblatt is board certified in internal medicine
and rheumatology.
Aclaris also announced today that it now expects preliminary
topline data for the ATI-450-RA-201 trial, its Phase 2a trial of
ATI-450, an investigational oral MK2 inhibitor, in subjects with
moderate to severe rheumatoid arthritis, in January 2021.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical
company developing a pipeline of novel drug candidates to address
the needs of patients with immuno-inflammatory diseases who lack
satisfactory treatment options. The company has a multi-stage
portfolio of drug candidates powered by a robust R&D engine
exploring protein kinase regulation. For additional information,
please visit www.aclaristx.com.
Cautionary Note Regarding Forward-Looking
Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
as that term is defined in the Private Securities Litigation Reform
Act of 1995. These statements may be identified by words such as
“believe,” “expect,” “intend,” “may,” “plan,” “potential,” “will,”
and similar expressions, and are based on Aclaris' current beliefs
and expectations. These forward-looking statements include
expectations regarding the development of Aclaris’ drug candidates,
including the timing of preliminary topline data from the
ATI-450-RA-201 trial. These statements involve risks and
uncertainties that could cause actual results to differ materially
from those reflected in such statements. Risks and uncertainties
that may cause actual results to differ materially include
uncertainties inherent in the conduct of clinical trials, Aclaris’
reliance on third parties over which it may not always have full
control, Aclaris’ ability to enter into strategic partnerships on
commercially reasonable terms, the uncertainty regarding the
COVID-19 pandemic and other risks and uncertainties that are
described in the Risk Factors section of Aclaris’ Annual Report on
Form 10-K for the year ended December 31, 2019, Aclaris’ Quarterly
Report on Form 10-Q for the quarter ended September 30, 2020, and
other filings Aclaris makes with the U.S. Securities and Exchange
Commission from time to time. These documents are available under
the “SEC filings” page of the Investors section of Aclaris’ website
at http://www.aclaristx.com. Any forward-looking statements speak
only as of the date of this press release and are based on
information available to Aclaris as of the date of this release,
and Aclaris assumes no obligation to, and does not intend to,
update any forward-looking statements, whether as a result of new
information, future events or otherwise.
Aclaris Contact
investors@aclaristx.com
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Sep 2023 to Sep 2024